SNTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Senti Biosciences's change in receivables for the quarter that ended in Mar. 2024 was $0.02 Mil. It means Senti Biosciences's Accounts Receivable declined by $0.02 Mil from Dec. 2023 to Mar. 2024 .
Senti Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.93 Mil. It means Senti Biosciences's Accounts Receivable increased by $0.93 Mil from Dec. 2022 to Dec. 2023 .
Senti Biosciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.08 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Senti Biosciences's liquidation value for the three months ended in Mar. 2024 was $-22.31 Mil.
The historical data trend for Senti Biosciences's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Change In Receivables | -0.01 | -0.40 | -0.13 | -0.93 |
Senti Biosciences Quarterly Data | |||||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | -0.14 | 0.20 | -2.16 | 1.16 | 0.02 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences (NAS:SNTI) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Senti Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.076 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Senti Biosciences's accounts receivable are only considered to be worth 75% of book value:
Senti Biosciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 23.723 | - | 46.091 | + | 0.75 * 0.076 | + | 0.5 * 0 |
= | -22.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Senti Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Kanya Rajangam | officer: Chief Medical & Devt. Officer | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Aktiengesellschaft Bayer | 10 percent owner | BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368 |
Susan D Berland | director | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Timothy K Lu | director, officer: CEO and President | SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
James J. Collins | director | C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Bayer World Investments B.v. | 10 percent owner | ENERGIEWEG 1, MIJDRECHT P7 3641 |
Deborah Knobelman | officer: Chief Financial Officer | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Herberts Curt A. Iii | officer: Chief Operating Officer | 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804 |
Brenda Cooperstone | director | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Philip J Lee | officer: Chief Technology Officer | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Edward T Mathers | director | C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Mohamad Makhzoumi | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Nea 15 Gp, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
From GuruFocus
By Stock market mentor Stock market mentor • 02-01-2023
By PurpleRose PurpleRose • 08-19-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 05-09-2023
By Marketwired • 09-27-2023
By sperokesalga sperokesalga • 05-20-2023
By Value_Insider Value_Insider • 10-28-2022
By Marketwired • 09-26-2023
By Stock market mentor Stock market mentor • 01-27-2023
By sperokesalga sperokesalga • 03-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.